Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma

BACKGROUND: Most glioblastoma tumours exhibit intrinsic phosphatidylinositol 3-kinase (PI3K) pathway activation. Preclinical in vitro and in vivo models suggest that buparlisib (an oral pan-PI3K inhibitor) can have an effect on glioblastoma directly and by enhancing the activity of radiation and of...

Descripción completa

Detalles Bibliográficos
Autores principales: Wen, Patrick Yung, Rodon, Jordi A, Mason, Warren, Beck, Joseph T, DeGroot, John, Donnet, Valerie, Mills, David, El-Hashimy, Mona, Rosenthal, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359189/
https://www.ncbi.nlm.nih.gov/pubmed/32661186
http://dx.doi.org/10.1136/esmoopen-2020-000673

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359189/
https://www.ncbi.nlm.nih.gov/pubmed/32661186
http://dx.doi.org/10.1136/esmoopen-2020-000673

Ejemplares similares